. Quote from Pierre-Alain Ruffieux, Chief Executive Officer, Lonza: “We congratulate Moderna on this important milestone, which represents a significant scientific achievement and serves as a testament to Moderna’s commitment to controlling the COVID-19 pandemic. “We are proud to support Moderna in the production of mRNA-1273. Our collaboration will allow for the manufacture […]
continue readingLonza Welcomes New Group Chief Executive Officer Pierre-Alain Ruffieux
Pierre-Alain Ruffieux today commences his role as Chief Executive Officer, following his appointment in June 2020. Albert M. Baehny resumes his role as Chairman of the Board of Directors, after a year in the role of Chief Executive Officer ad interim. Quote from Albert Baehny, Chairman of the Board of Directors, Lonza: “I would like […]
continue readingInvestor Update Details Business Structure, Divisional Dynamics, New External Reporting and Guidance
Lonza provides the details of its new structural design, culture and external reporting 2023 Group guidance: double-digit sales growth, CORE EBITDA margin of around 33% – 35% and double-digit ROIC CAPEX in 2021 and 2022 is likely to remain at 2019 levels Biologics and Small Molecules are primary growth drivers, with contracted business up high […]
continue readingLonza’s Pharma Biotech Business Drives Strong H1 2020 Group Sales Growth and Margin Improvement
Strong operational performance maintained during COVID-19; sites remained open and protection of employees continues to be a top priority Landmark ten-year collaboration with Moderna on the mRNA1 platform. The current focus is to manufacture an mRNA-based vaccine (mRNA-1273) for the novel coronavirus Group sales growth of 7.7%2 and resilient CORE EBITDA margin of 29.1% Growth driven by […]
continue readingSven Abend Leaves Lonza to Take CEO Position in Germany
• Sven Abend has decided to resign from Lonza to take a CEO position in Germany. • Recruitment plans are under way to appoint a permanent replacement. • LSI is performing well and the segment carve-out process is nearing completion. Sven Abend has decided to resign from his position as a member of the Executive […]
continue readingLonza Appoints New Chief Executive Officer
The Board of Lonza announced today that Pierre-Alain Ruffieux has been appointed Chief Executive Officer effective 1 November 2020. Pierre-Alain is currently Head of Global Pharma Technical Operations at Roche where he and his 12,000-strong team are responsible for all aspects of pharmaceutical commercial manufacturing and supply chain operations, technical, quality assurance and regulatory. […]
continue readingMoncef Slaoui to Step Down as Member of the Board of Directors of Lonza Group
Dr Moncef Slaoui has decided to step down from his position as a member of the Lonza Group Board of Directors, following his appointment to the role of Chief Advisor for the U.S. government’s “Warp Speed” national vaccine program. Lonza Group wishes Dr Slaoui every success in his new role. Über Lonza Group Ltd. At […]
continue reading